The 2026 State of 340B Compliance: What’s Working, What Isn’t, and Where the Gaps Are Widening

14 Jul The 2026 State of 340B Compliance: What’s Working, What Isn’t, and Where the Gaps Are Widening

340B compliance in 2026 demands more than enrollment and policy documentation. Covered entities must maintain real-time oversight of patient eligibility, contract pharmacy arrangements, and audit-ready documentation. All under intensified HRSA scrutiny. Organizations treating compliance as a periodic exercise rather than a continuous operational function are the ones generating findings.

Key Takeaways

• HRSA audit findings most commonly trace to patient eligibility documentation gaps and contract pharmacy oversight failures. Not intentional misuse
• The financial stakes of losing 340B access are significant, given the drug pricing discounts the program provides to covered entities serving vulnerable populations
• Organizations that build compliance into daily operations consistently outperform those that treat it as a pre-audit scramble
• Waiting until an audit notice arrives to address compliance gaps is the most expensive decision a covered entity can make
• The gap between being compliant and being able to prove compliance is where most programs get hurt

Why Is 340B Compliance Harder to Get Right Now Than It Was Five Years Ago?

The program’s foundational rules haven’t changed dramatically. What’s changed is the density of obligations layered around them. And the sophistication of how HRSA tests for compliance.

Manufacturer restrictions on contract pharmacy arrangements, which accelerated significantly after 2020, have created a fragmented landscape that covered entities must track individually. Some manufacturers restrict contract pharmacy access entirely for certain covered entity types. Others require claims data submissions through third-party administrators as a precondition of participation. The burden of monitoring each manufacturer’s current position, and documenting your organization’s compliance with it, simply didn’t exist at this scale a few years ago.

HRSA’s audit program has matured in parallel. Early audit cycles focused on foundational eligibility questions. Current audits go considerably deeper. Into split-billing software configurations, into the specificity of written policies and procedures, into whether your oversight is contemporaneous and documented rather than reconstructed after the fact.

The organizations generating findings today aren’t, for the most part, running bad programs. They’re running programs designed for a simpler compliance environment. That’s the core problem. The infrastructure hasn’t kept pace with the scrutiny.

What Does a Compliance Failure Actually Look Like Before HRSA Shows Up?

It rarely looks like anything at all. That’s what makes it dangerous.

Consider a typical community health center operating a 340B program with three contract pharmacy locations. The program was set up correctly. Policies exist. The TPA is processing claims. But over time, patient eligibility criteria have drifted slightly in how front-desk staff apply them day to day. The written policy says one thing; the operational practice is something subtly different. No one flagged it because no one was measuring the gap between the two.

When HRSA audits, they don’t just read your policy. They test it against actual dispensing records. That gap between documented policy and operational practice is exactly where most findings live.

A second pattern that appears regularly: a covered entity’s contract pharmacy arrangement with a specific manufacturer requires claims data submission within a defined window. The TPA submits on schedule. But no one at the covered entity is verifying that submissions are complete, timely, and matched against the manufacturer’s current requirements. The manufacturer’s position shifts. The covered entity keeps operating under the old assumption.

Neither situation involves bad intent. Both generate audit findings. And both are entirely preventable with the right oversight structure in place before HRSA asks the question.

What Separates Zero-Finding Programs from the Rest?

The difference isn’t program size or simplicity. It’s whether compliance is treated as infrastructure or as a response to threat.

Programs that consistently achieve clean audits share three structural characteristics, which together form what experienced 340B practitioners refer to as a compliance operations model:

Named ownership. Every compliance obligation. Patient eligibility verification, contract pharmacy oversight, manufacturer restriction tracking, annual recertification. Has a designated owner. Not a department. A person with defined accountability for that specific function.

Measurement cadence. Key compliance metrics are reviewed on a defined schedule as operational KPIs, not assembled for audit prep. Eligibility error rates, contract pharmacy claim reconciliation rates, and policy-to-practice alignment are tracked continuously, not retrospectively.

Evidence architecture. Documentation is built to survive HRSA scrutiny, not just to satisfy internal review. That means contemporaneous records, version-controlled policies with documented review dates, and a clear chain of evidence connecting each program rule to how it’s executed operationally.

This isn’t a theoretical framework. It reflects what 340B compliance monitoring actually looks like when it’s functioning as an operational discipline rather than a calendar event. The root cause of most compliance failures isn’t negligence. It’s diffuse accountability across roles that were never designed to own 340B compliance in full. Structural clarity fixes that directly.

Isn’t My TPA Handling This?

This is one of the most consequential misunderstandings in 340B program management, and it’s worth being direct about it.

Your TPA manages claims processing. That’s the scope of what they’re contracted to do. They’re not your compliance officer, your policy author, or your HRSA audit defense. When HRSA audits your program, they’re auditing your covered entity. The accountability sits with you.

TPAs don’t typically monitor manufacturer restriction changes and alert you when your current arrangement has fallen out of step. They don’t review your patient eligibility policies against your actual dispensing patterns. They don’t prepare your audit response documentation. A clean claims record from your TPA doesn’t translate to audit readiness.

Understanding what 340B independent external audits actually examine makes this boundary clear. The gap between TPA coverage and covered entity responsibility is consistently larger than program managers expect. And it’s that gap that HRSA audit protocols are specifically designed to probe.

What’s Stopped Working: Three Approaches That Used to Be Enough

Annual self-audits without external validation. The complexity introduced by manufacturer restrictions and evolving HRSA audit focus areas has outpaced what most internal teams can objectively assess. Self-audits catch the problems you know to look for. External reviews catch the ones you don’t.

Static policy documentation. Policies written in 2021 and reviewed on a calendar schedule don’t account for the rate of manufacturer restriction changes or shifts in HRSA’s audit priorities. Policies need to function as living documents with review cycles tied to regulatory developments, not to arbitrary dates.

Reactive compliance posture. Waiting for an audit notice to conduct a serious compliance review is operationally equivalent to waiting for a fire to test your sprinkler system. By the time HRSA is at your door, your options for addressing gaps are substantially narrower. The savings are real. The compliance gaps that accumulate alongside them are just as quiet.

With Expert Support vs. Without: What the Outcomes Actually Look Like

The cost of expert support is defined and bounded. The cost of an audit finding. Repayment demands, potential program termination, reputational damage to an organization serving vulnerable populations. Isn’t bounded at all.

Who This Matters Most For

340B compliance support is most critical for covered entities in three situations: those who’ve received an HRSA audit notice and need immediate, structured response capability; those with prior audit findings who need to demonstrate corrective action; and those whose programs have grown in complexity. More contract pharmacy locations, more manufacturer arrangements, more patient volume. Without a corresponding investment in compliance infrastructure.

If your program is smaller and operating with minimal contract pharmacy complexity, the compliance burden is lighter. But lighter doesn’t mean absent. The foundational requirements. Patient eligibility documentation, annual recertification, written policies and procedures. Apply regardless of program size. And the current regulatory environment means that “we’ve never had a finding” isn’t the same as “we’re compliant.” It means you haven’t been tested recently, or that your last audit didn’t surface what currently exists.

One honest caveat: no credible consultant can guarantee zero findings. The compliance environment involves HRSA judgment calls, documentation judgment calls, and operational realities that no outside party fully controls. What expert support produces is the strongest possible documented position before, during, and after an audit. That’s a meaningfully different outcome than going in unprepared. But it’s not a guarantee, and you should be skeptical of anyone who frames it as one.

FAQ

How do I know if my 340B program is actually audit-ready right now?

Audit readiness means you can produce contemporaneous documentation for every obligation HRSA will test. Patient eligibility, contract pharmacy oversight, written policies, recertification records. Without reconstructing anything after the fact. If you’d need to gather or recreate records in response to an audit notice, you’re not audit-ready. A structured pre-audit review against HRSA’s published audit protocol is the most reliable way to find out where you actually stand.

What are HRSA auditors looking for in a current audit cycle?

HRSA audits test whether your operational practices match your written policies, whether patient eligibility is being applied correctly and consistently, and whether your contract pharmacy arrangements comply with both program rules and applicable manufacturer restrictions. They’re also specifically assessing whether your oversight is real-time and documented. Not just whether policies exist on paper.

Can I appeal an audit finding, and what do successful appeals look like?

Yes, covered entities can appeal HRSA audit findings through a formal dispute resolution process. The odds of a successful appeal depend heavily on the quality of your documentation and the specificity of your response. Ponaman Healthcare Consulting carries an 80% success rate in overturning audit findings. Which reflects what a structured, documented appeal looks like compared to an ad hoc response built under pressure.

How long does it take to get a program into a defensible compliance posture?

It depends on where the gaps are. Programs with foundational documentation already in place can typically address specific compliance weaknesses within a few months of focused effort. Programs with systemic gaps. Diffuse accountability, outdated policies, no ongoing monitoring infrastructure. Take longer. There’s no honest universal timeline, but the earlier the process starts, the more options remain available.

What’s the difference between a TPA audit and an HRSA audit?

A TPA audit reviews claims processing accuracy within your contract pharmacy arrangements. It’s a financial and operational check on how claims are handled. An HRSA audit is a federal compliance review of your entire 340B program. Eligibility, policies, oversight, and program integrity. A clean TPA audit doesn’t translate into HRSA audit readiness.

My organization hasn’t had a finding in years. Doesn’t that mean we’re in good shape?

It means you haven’t been audited recently, or that your last audit didn’t surface what currently exists. The compliance environment has shifted considerably. Particularly around contract pharmacy and manufacturer restrictions. A clean audit history is worth something, but it’s not a substitute for current, documented compliance infrastructure in a regulatory environment that’s meaningfully different from what it was three years ago.

What should I do first if I’ve just received an HRSA audit notice?

Don’t wait, and don’t make changes. The first priority is preserving all documentation in its current state. Don’t update, revise, or “clean up” policies or records in response to the notice. Engage experienced 340B audit support immediately. HRSA’s response timeline is short, and the quality of your initial response shapes the entire audit trajectory. This is the exact situation where 340B program integrity audit support from a team with documented audit experience produces measurably different outcomes than navigating it alone.

Where Your Program Actually Stands

You’ve just read a detailed account of where 340B compliance breaks down and why the approaches that worked before aren’t sufficient now. The natural next question isn’t abstract. It’s specific to your program.

Ponaman Healthcare Consulting has supported 148 HRSA 340B audits. Sixty-seven percent of clients achieve audits with zero findings. That doesn’t happen by accident. It happens because compliance infrastructure was built and maintained before HRSA arrived. Not after.

If you want to know what your program’s actual exposure looks like right now, contact Ponaman Healthcare Consulting for a compliance review. Not to prepare for an audit you might never face. Because the savings your program generates for your patients depend on the program staying intact. And that’s worth knowing before the audit notice lands.

Ponaman Healthcare Consulting is a specialized 340B program compliance and consulting firm serving covered entities across the full program lifecycle. From enrollment and implementation through HRSA audit defense and appeals. Their team of consultants, auditors, analysts, and medical and legal specialists works with community health centers, hospitals, and underserved healthcare organizations to protect program integrity and maximize the benefits of 340B participation through a data-driven, metrics-focused approach.